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Abstract
A tumor consisting of an adenocarcinoma component and a neuroendocrine carcinoma component, with each
component accounting for at least 30% of the tumor, is defined as a mixed adenoneuroendocrine carcinoma
(MANEC). We report a case of MANEC of the pancreas. A 63-year-old man presented with hyperglycemia and was
referred to our hospital for further examination. Abdominal contrast-enhanced computed tomography (CT) revealed
a mass of 2 cm in size in the pancreas head with portal vein narrowing. Fluorin-18 fluorodeoxyglucose-positron
emission tomography (FDG-PET) CT revealed increased accumulation in the mass of the pancreas head. Endoscopic
retrograde cholangiopancreatography (ERCP) showed severe narrowing of the main pancreatic duct. Cytological
analysis by endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) suggested a neuroendocrine
tumor. Under the diagnosis of neuroendocrine tumor, pancreaticoduodenectomy with portal vein resection and
regional lymph node dissection was performed with curative intent. Histological examination revealed that the
tumor consisted of two cell populations. One was well- to moderately differentiated tubular adenocarcinoma. This
cell component accounted for 45% of the whole tumor. The second component was non-adenocarcinoma cells
arranged in a nest, and the cells had round nuclei, abundant cytoplasm, and coarse chromatin. The Ki67 labeling
index was 40%. Immunohistochemically, the adenocarcinoma cells were positive for CEA but negative for
chromogranin A (CgA) and synaptophysin (Syn), while the non-adenocarcinoma cells were positive for the
expression of CgA and Syn but negative for CEA. Based on the findings, a diagnosis of MANEC of the pancreas was
made. Postoperatively, lymph node metastasis and peritoneal dissemination developed rapidly and he died the
6 months after the operation. Due to the small number of reported cases of MANEC of the pancreas, its clinical
behavior remains unclear and a standardized management protocol has not been established. Further investigation
of more cases of this rare entity is necessary.
Background
In the 2010 World Health Organization (WHO) classifi-
cation of neuroendocrine neoplasms in the digestive
system [1], tumors consisting of an adenocarcinoma
component and a neuroendocrine carcinoma compo-
nent, in which each component accounts for at least
30% of the tumor, are defined as mixed adenoneuroen-
docrine carcinomas (MANECs) [1]. MANECs can occur
in various organs including the gallbladder [2], bile duct
[3], stomach [4], colon [5], and cecum [6]. This classifi-
cation also applies to pancreatic neuroendocrine
neoplasms. However, MANEC located in the pancreas is
extremely rare. Herein, we report a case of MANEC of
the pancreas and present a brief literature review.
Case presentation
A 63-year-old man presented with hyperglycemia and
was referred to our hospital for further examination in
April 2015. He had no past history including pancreatic
disorders. Laboratory tests showed the following: pan-
creatic amylase, 291 IU/l (normal range, 40–129 IU/l);
BS, 219 mg/dl (70–109 mg/dl); and HbA1c, 7.5% (4.6–
6.2%). Serum level of the tumor marker carcinoembryo-
nic antigen (CEA), 4.7 ng/ml, was within normal range
(<5.0 ng/ml), while serum levels of the tumor markers
carbohydrate antigen 19-9 (CA19-9), 51.1 U/ml (<37 U/
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ml), DUPAN-2, 53 U/ml (<25 U/ml), and SPAN-1,
45.9 U/ml (<10 U/ml), were slightly elevated.
Abdominal contrast-enhanced computed tomography
(CT) showed diffuse enlargement of the pancreas with
increased CT level in peri-pancreatic fatty tissue and re-
vealed a mass of 2 cm in size in the pancreas head. The
mass was poorly enhanced in the arterial phase and was
gradually enhanced in the venous phase. The portal vein
showed narrowing, suggestive of tumor invasion (Fig. 1).
FDG-PET CT revealed increased accumulation in the
mass of the pancreas head (Fig. 2a). Endoscopic retro-
grade cholangiopancreatography (ERCP) showed severe
narrowing of the main pancreatic duct (Fig. 2b). Cy-
tology of pancreatic juice collecting during the ERCP did
not reveal malignant cells. Cytological analysis by means
of endoscopic ultrasonography-guided fine-needle aspir-
ation (EUS-FNA) suggested a neuroendocrine tumor
(G2) (Fig. 2c, d).
Under the diagnosis of a neuroendocrine tumor, pan-
creaticoduodenectomy with portal vein resection and
regional lymph node dissection was performed with
curative intent. Macroscopically, a 2-cm-sized mass in
the pancreas head was presented as the resected speci-
men. Histological examination revealed that the tumor
consisted of two cell populations (Fig. 3). One was well-
to moderately differentiated tubular adenocarcinoma.
The adenocarcinoma cells were arranged in an irregular
pattern and accounted for 45% of the whole tumor
(Fig. 3b). The other cell population was non-
adenocarcinoma cells arranged in a nest, and the cells
had round nuclei, abundant cytoplasm, and coarse chro-
matin (Fig. 3c). An intermixed central zone exists
between the two cell components (Fig. 3d). Immunohis-
tochemically, the adenocarcinoma cells were positive for
CEA but negative for chromogranin A (CgA) and synap-
tophysin (Syn), while the non-adenocarcinoma cells were
positive for the expression of CgA and Syn but negative
for CEA (Fig. 4a–c). The Ki67 labeling index was 40%
(Fig. 4d). Based on these findings, a diagnosis of MANEC
of the pancreas was made. The portal vein, duodenum,
and peripheral lymph nodes were infiltrated by neuroen-
docrine carcinoma cells. The final pathological stage was
T4 N2 M0 stage IVb according to the General Rules for
the Study of Pancreatic Cancer in Japan [7].
The patient’s postoperative course was eventful, and
he was discharged on the 34th day after the operation.
He underwent adjuvant chemotherapy consisting of a
combination irinotecan and cisplatin. However, he
refused to continue chemotherapy after the completion
of one course. Lymph node metastasis and peritoneal
dissemination developed rapidly, and he died 6 months
after the operation.
Discussion
The term MANEC was introduced by the 2010 WHO
classification of neuroendocrine neoplasms in the digest-
ive system [1]. Neuroendocrine tumors are classed as
NET G1 (carcinoid, mitotic count of <2 per 10 high
power fields (HPF) and/or a Ki67 index of ≤2%); NET
G2 (mitotic count of 2–20 per 10 HPF and/or a Ki67
index of 3–20%); and NET G3 (neuroendocrine carcin-
oma, mitotic count of >20 per 10 HPF and/or a Ki67
index of >20%). Furthermore, tumors with two malig-
nant components, adenocarcinoma and neuroendocrine
carcinoma, with each component accounting for at least
30% of the tumor, are defined as MANECs [1].
The pancreas is composed of exocrine and endocrine
gland components. The exocrine part consists of ductal
Fig. 1 Abdominal contrast-enhanced computed tomography (CT) showed diffuse enlargement of the pancreas with increased CT level in the
peri-pancreatic fatty tissue and revealed a mass of 2 cm in size in the pancreas head (c–d, arrow). The mass was poorly enhanced in the arterial
phase and was gradually enhanced in the venous phase. The portal vein showed narrowing (b–f, arrowhead)
Imaoka et al. Surgical Case Reports  (2016) 2:133 Page 2 of 6
and acinar cells, and the endocrine part consists of islet
cells. Most pancreatic tumors usually originate in one of
these cell types. Pancreatic tumors containing both exo-
crine and endocrine components are rare. Cubilla and
Fitzgerald reported that mixed cell type carcinomas
accounted for only 0.2% of all pancreatic tumors [8].
These types of neoplasms are categorized as combined
neoplasms of the pancreas in the General Rules for the
Study of Pancreatic Cancer in Japan [7]. These tumors
have been described by the terms “mixed duct-acinar
tumors,” “duct-islet tumors,” “acinar-islet tumors,” and
“duct-acinar-islet cell tumors,” based on their components.
Fig. 2 PET-CT revealed increased accumulation in the mass of the pancreas head (maximum standardized uptake value (SUV max): 5.6 (initial)
and 7.8 (delayed) (a). Endoscopic retrograde cholangiopancreatography (ERCP) showed severe narrowing and obstruction of the main pancreatic
duct by the tumor (arrow) (b). Endoscopic ultrasonography (EUS) showed the tumor as a low echoic mass (c). Cytological analysis by means of
EUS-guided fine-needle aspiration (FNA) suggested a neuroendocrine tumor (G2) (d)
Fig. 3 Macroscopically, a 2-cm-sized mass in the pancreas head was presented as the resected specimen. Histological examination revealed that
the tumor consisted of two cell populations. The white-shaded area indicates a component of well- to moderately differentiated tubular adenocarcinoma
cells and the gray-shaded area indicates a component of non-adenocarcinoma cells (a). The adenocarcinoma cells were arranged in an irregular pattern
(b). Non-adenocarcinoma cells are arranged in a nest, and the cells had round nuclei, abundant cytoplasm, and coarse chromatin (c). An intermixed central
zone exists between the two cell components (d) (asterisk part in Fig. 3a)
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Among them, to the best of our knowledge, only four cases
including our case are compatible with MANEC [9–11].
The clinicopathologic features of the four cases are
summarized in Table 1. Three patients were males and
one patient was female. The mean age of the patients
was 62.5 years (range, 52–72 years). The mean size of
the tumors was 2.1 cm (range, 2.0–2.5 cm). The
locations were the pancreas body in three cases and the
pancreas head in one case. Three of the four patients
were asymptomatic. The tumors were incidentally de-
tected by a CT scan during follow-up for other diseases.
Generally, pancreatic neuroendocrine tumors are classi-
fied as either functional or non-functional depending on
their ability to secrete biologically active hormones. Our
patient presented with hyperglycemia, but he did not
satisfy the criteria of glucagonoma syndrome. All cases
including our case lacked distinct or functional
hormones.
Radiological examinations are useful for the diagnosis
of pancreatic tumors. Neuroendocrine tumors are typic-
ally well-circumscribed lesions that appear hyperenhan-
cing on contrast-enhanced CT and show little change in
the main pancreatic duct on endoscopic retrograde
pancreatography (ERP). Narrowing or obstruction of the
pancreatic duct is rare [12]. On the other hand, adeno-
carcinomas are typically hypovascular lesions on
contrast-enhanced CT and show severe stenosis or
obstruction in the main pancreatic duct on ERP. In cases
of MANEC, radiological findings have both features of
neuroendocrine carcinoma and adenocarcinoma. Imaging
Fig. 4 Immunohistochemically, the non-adenocarcinoma cell components were positive for the expression of CgA and Syn (a, b), but negative
for CEA (c). The Ki67 labeling index was 40% (d)
















1 63, female Body, 2 cm DP Collision ~40 NEC S-1 (–) Alive (8) 2010, Terashi
[9]
2 52, male Body, 2.5 cm DP Collision 30 ND GEM (–) Alive (9) 2012, Watanabe
[10]
3 72, male Body, 2 cm DP Collision 30 (–) S-1 (–) Alive (8) 2015, Shibuya
[11]
Our case 63, male Head, 2 cm PD Collision 55 NEC CPT-11 + CDDP Peritoneal
dissemination
Dead (6)
DP distal pancreatectomy, PD pancreaticoduodenectomy, NEC neuroendocrine carcinoma, GEM gemcitabine, CPT-11 irinotecan, CDDP cisplatin, ND not described
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dynamics of contrast-enhanced CT vary depending on the
ratios of neuroendocrine carcinoma cells and adenocar-
cinoma cells. Hence, diagnosis by means of only radio-
logical examinations is difficult.
Recently, EUS-FNA has been reported to be a useful
diagnostic tool for pancreatic tumors [13]. In case 3,
MANEC was successfully diagnosed preoperatively by
means of EUS-FNA. In our case, contrary to the final
diagnosis, cytological analysis by EUS-FNA suggested a
neuroendocrine tumor (G2). This may suggest that FNA
has some limitations for making a definite diagnosis,
because FNA cytology cannot cover the entire tumor.
The confirmed diagnosis mainly depends on histopatho-
logical and immunohistochemical analyses from a surgi-
cally resected specimen. Furthermore, it is impossible to
determine whether each component accounts for at least
30% if it cannot be resected completely.
The histogenesis of MANEC of the pancreas is still
controversial. It was suggested in previous reports that
associated exocrine and endocrine neoplasms of the
pancreas arise from totipotent pancreatic stem cells,
which reside in the pancreatic duct and islets [14, 15].
Therefore, tumors containing both exocrine and endo-
crine components can develop in the pancreas. Chang et
al. proposed a classification system of tumor histogenesis
for associated exocrine and endocrine neoplasms that
consists of five types: amphicrine type, mixed type, colli-
sion type, solitary concomitant type, and multiple con-
comitant type [16]. Among them, the collision type
shows the endocrine part at one end and the exocrine
part at the other end, with an intermixed central zone.
Our case can be classified as a collision type.
Due to the small number of cases of reported
MANEC, the clinical behavior is unclear. At present, it
is generally agreed that surgery is the first line of treat-
ment for cases with a resectable tumor (Table 1). After
radical resection, multimodal treatment with adjuvant
radiotherapy and/or chemotherapy should be performed.
However, it is still not clear whether the postoperative
course and ideal management of cases of MANEC differ
from those of cases of ductal adenocarcinoma only or
neuroendocrine carcinoma only. Postoperative chemo-
therapies for ductal adenocarcinoma are now almost
established [17, 18]. Also, in cases of neuroendocrine
carcinoma, the efficacy of chemotherapeutic combin-
ation regimens such as etoposide plus cisplatin and
irinotecan plus cisplatin has been reported [19, 20]. Lee
et al. proposed that treatment should focus on the more
aggressive cells of the tumor because the clinical out-
come of this mixed tumor follows that of a more aggres-
sive cell type [4]. In our case, the neuroendocrine
carcinoma component mainly occupied the tumor and
infiltrated the portal vein, duodenum, and peripheral
lymph nodes, while the adenocarcinoma component was
not seen in the infiltrated region. Accordingly, a combin-
ation regimen of irinotecan and cisplatin was adminis-
tered to the patient. However, he refused to continue the
chemotherapy, and lymph node metastasis and periton-
eal dissemination developed rapidly. He died 6 months
after the operation. Our case indicated that MANEC of
the pancreas may be a tumor with high malignant
potential. The long-term postoperative courses have not
been fully described in reported cases, and it is therefore
unclear whether the prognosis of MANEC is pessimistic
or not. Further investigation of more cases of this rare
entity is necessary.
Conclusions
We have reported a case of MANEC of the pancreas.
MANEC of the pancreas is extremely rare, and the
clinical behavior remains unclear. Accumulation of
additional data from more cases is necessary to further
elucidate this type of tumor and standardize optimal
therapy.
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